Symbolbild · KI-generiert
Sectors · Clinical development, regulatory approval and medical technology
Biotech & Pharma stocks: small caps at a glance
Kurz gefasstBiotech small-caps are news-driven: trial data and approval decisions frequently move the share price by double digits — in either direction. Knowing the calendar means understanding the share price.
412 companies in the directory
25 articles
5 typical price drivers
What belongs in this sector
The sector covers clinical-stage biotech companies, drug developers, medical technology and diagnostics. Many of these companies generate no revenue yet: their value lies in the pipeline — the drug candidates currently in development. Funding comes from the capital markets and partnerships, not from ongoing operations.
What moves the share price
These are the events that typically move share prices in the Biotech & Pharma sector:
Trial data (Phase I / II / III)
The most important share price driver. Phase I tests safety, Phase II tests whether the drug works in principle, and Phase III tests effectiveness at large scale.
Regulatory decision (FDA / EMA)
Important to note: a submitted application is not the same as a granted approval. Months separate the two, and rejection is a real possibility.
Advisory committee (Adcom)
A panel of experts makes a recommendation to the regulator. The vote is not binding, but the market often treats it as a near-final decision.
Trial discontinuation
Can stem from safety concerns, but may simply reflect a lack of efficacy — the distinction matters greatly for the rest of the pipeline.
Licensing or partnership deal
A pharmaceutical company takes over development or commercialisation. This brings in money and validates the science, but gives away a share of future revenues.
The key figures that matter here
| Development phase | The later the phase, the higher the statistical probability of success — and the higher the share price tends to be. |
|---|---|
| Primary endpoint | The pre-defined goal of the trial. Only meeting it counts; a missed primary endpoint cannot be rescued by positive secondary findings. |
| Cash runway | Does the company have enough cash to reach the next data readout? If not, a capital increase (Kapitalerhöhung) is likely. |
| Patent life | Determines how long an approved drug can be sold exclusively before generic competition is permitted. |
Risiken des Sektors
The majority of all drug candidates never reach the market. A single negative trial result can wipe out most of a company's market value. On top of that, capital increases (Kapitalerhöhungen) are a regular occurrence, and outcomes depend heavily on the decisions of individual regulators. Topline data are also just a summary — the full dataset can tell a very different story.
Recent articles
FDA Approval as a Turning Point: What Inovio's VOCERYQ Teaches Biotech Investors 01.11.2026 China Biotech Restrictions: What Licence Exemptions Mean for Cross-Border Deals 24.10.2026 Understanding Dilution: What Pre-Funded Warrants Cost Biotech Investors 14.10.2026 Radiopharmaceuticals in Phase 3: What BMS' RayzeBio Deal Teaches Us 12.10.2026 China's $500 Billion Biotech Plan: Why IP Strategy Is What Really Counts 19.09.2026Companies in this sector
412 listed small and micro caps in this sector, ordered by market capitalisation.
| companies | Ticker | Börse |
|---|---|---|
| ADMA Biologics Inc | ADMA | NASDAQ |
| HUTCHMED (China) Limited | HCM | NASDAQ |
| Aurinia Pharmaceuticals Inc | AUPH | NASDAQ |
| GH Research PLC | GHRS | NASDAQ |
| Genus plc | LSE | |
| Tyra Biosciences, Inc. | TYRA | NASDAQ |
| 4DMEDICAL LIMITED | 4DX | ASX |
| UroGen Pharma Ltd. | URGN | NASDAQ |
| SELLAS Life Sciences Group, Inc. | SLS | NASDAQ |
| Nanobiotix S.A. | NBTX | NASDAQ |
| Mesoblast Limited | MESO | NASDAQ |
| Kardigan, Inc. | KARD | NASDAQ |
Andere Sektoren
Educational content only, not investment advice. Small caps are highly speculative and total loss is possible. All information without warranty.